Market Overview

UPDATE: Goldman Sachs Reiterates Sell Rating, $62 PT on Humana

Share:
Related HUM
PE Firm Sets Ventures With Select Medical, Tenet Healthcare
Barclays Raises Price Targets On Healthcare Companies
Tenet Plays The Doctor Glut (Seeking Alpha)

In a report published Wednesday, Goldman Sachs Group reiterated its Sell rating and $62.00 price target on Humana (NYSE: HUM).

Goldman Sachs noted, “The focus of the investor day was the transition to provider-integrated care (owned and risk-contracted) that offers lower cost / higher quality outcomes versus traditional fee-for-service. With Medicare Advantage (MA) driving the majority of revenue and earnings, we think integrated care is the right model to better position Humana for tighter MA reimbursement as health reform rolls through and also the right model to strengthen Humana's role in easing the national Medicare cost crisis in the years ahead.”

Humana closed on Tuesday at $68.29.

Latest Ratings for HUM

DateFirmActionFromTo
Mar 2015BarclaysMaintainsEqual-weight
Jan 2015BarclaysMaintainsEqual-weight
Jan 2015Deutsche BankUpgradesSellHold

View More Analyst Ratings for HUM
View the Latest Analyst Ratings

Posted-In: Goldman Sachs GroupAnalyst Color Reiteration Analyst Ratings

 

Related Articles (HUM)

Around the Web, We're Loving...